Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
Abstract
:1. Introduction
2. Herpesviruses and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
2.1. HSV/VZV
2.2. CMV
2.3. HHV-6
3. Bispecific Antibodies
3.1. Blinatumomab
3.2. BsAb in Patients with Lymphoma
3.3. BsAb in Patients with Multiple Myeloma
4. Future Directions
Author Contributions
Funding
Conflicts of Interest
References
- Sassine, J.; Siegrist, E.A.; Shafat, T.F.; Chemaly, R.F. Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: Closer to the finish line? Clin. Microbiol. Infect. 2024, 31, 49–56. [Google Scholar] [CrossRef] [PubMed]
- Hill, J.A.; Li, D.; Hay, K.A.; Green, M.L.; Cherian, S.; Chen, X.; Riddell, S.R.; Maloney, D.G.; Boeckh, M.; Turtle, C.J. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018, 131, 121–130. [Google Scholar] [CrossRef] [PubMed]
- Vora, S.B.; Waghmare, A.; Englund, J.A.; Qu, P.; Gardner, R.A.; Hill, J.A. Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infect. Dis. 2020, 7, ofaa121. [Google Scholar] [CrossRef] [PubMed]
- Park, J.H.; Romero, F.A.; Taur, Y.; Sadelain, M.; Brentjens, R.J.; Hohl, T.M.; Seo, S.K. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Chimeric Antigen Receptor T Cells. Clin. Infect. Dis. 2018, 67, 533–540. [Google Scholar] [CrossRef] [PubMed]
- Wudhikarn, K.; Palomba, M.L.; Pennisi, M.; Garcia-Recio, M.; Flynn, J.R.; Devlin, S.M.; Afuye, A.; Silverberg, M.L.; Maloy, M.A.; Shah, G.L.; et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020, 10, 79. [Google Scholar] [CrossRef]
- Baird, J.H.; Epstein, D.J.; Tamaresis, J.S.; Ehlinger, Z.; Spiegel, J.Y.; Craig, J.; Claire, G.K.; Frank, M.J.; Muffly, L.; Shiraz, P.; et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021, 5, 143–155. [Google Scholar] [CrossRef] [PubMed]
- Kampouri, E.; Walti, C.S.; Gauthier, J.; Hill, J.A. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: Key points for clinicians. Expert. Rev. Hematol. 2022, 15, 305–320. [Google Scholar] [CrossRef] [PubMed]
- Gudiol, C.; Lewis, R.E.; Strati, P.; Kontoyiannis, D.P. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: Is there an excess risk for infection? Lancet Haematol. 2021, 8, e216–e228. [Google Scholar] [CrossRef] [PubMed]
- Strati, P.; Varma, A.; Adkins, S.; Nastoupil, L.J.; Westin, J.; Hagemeister, F.B.; Fowler, N.H.; Lee, H.J.; Fayad, L.E.; Samaniego, F.; et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 2021, 106, 2667–2672. [Google Scholar] [CrossRef]
- Khawaja, F.; Sassine, J.; Handley, G.; Iyer, S.P.; Ramdial, J.; Ahmed, S.; Nieto, Y.; Spallone, A.; Ariza Heredia, E.; Chemaly, R.F. Herpesviruses Infections in CAR T Cell Recipients. In Proceedings of the 2022 Tandem Meetings—Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Salt Lake City, UT, USA, 23–26 April 2022. [Google Scholar]
- Sassine, J.; Agudelo Higuita, N.I.; Siegrist, E.A.; Saeedi, A.; Corbisiero, M.F.; Connelly, P.; Bastias, A.G.; Dib, R.W.; Henao-Cordero, J.; Chastain, D.B.; et al. Timeline and outcomes of viral and fungal infections after Chimeric Antigen Receptor (CAR) T-cell therapy: A large database analysis. Clin. Microbiol. Infect. 2024; in press. [Google Scholar] [CrossRef]
- McKenna, M.; Epperla, N.; Ghobadi, A.; Liu, J.; Lazaryan, A.; Ibrahim, U.; Jacobson, C.A.; Naik, S.G.; Nastoupil, L.; Chowdhury, S.M.; et al. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br. J. Haematol. 2023, 202, 248–255. [Google Scholar] [CrossRef]
- Shahid, Z.; Jain, T.; Dioverti, V.; Pennisi, M.; Mikkilineni, L.; Kambhampati, S.; Shah, N.N.; Dadwal, S.; Papanicolaou, G.; Hamadani, M.; et al. Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies. Transplant. Cell. Ther. 2024, 30, 955–969. [Google Scholar] [CrossRef] [PubMed]
- Mumtaz, A.A.; Fischer, A.; Lutfi, F.; Matsumoto, L.R.; Atanackovic, D.; Kolanci, E.T.; Hankey, K.G.; Hardy, N.M.; Yared, J.A.; Kocoglu, M.H.; et al. Ocular adverse events associated with chimeric antigen receptor T-cell therapy: A case series and review. Br. J. Ophthalmol. 2023, 107, 901–905. [Google Scholar] [CrossRef]
- Heldman, M.R.; Ma, J.; Gauthier, J.; O’Hara, R.A.; Cowan, A.J.; Yoke, L.M.; So, L.; Gulleen, E.; Duke, E.R.; Liu, C.; et al. CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell Immunotherapy. J. Immunother. 2021, 44, 351–354. [Google Scholar] [CrossRef]
- Hill, J.A.; Krantz, E.M.; Hay, K.A.; Dasgupta, S.; Stevens-Ayers, T.; Bender Ignacio, R.A.; Bar, M.; Maalouf, J.; Cherian, S.; Chen, X.; et al. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019, 3, 3590–3601. [Google Scholar] [CrossRef]
- Walti, C.S.; Krantz, E.M.; Maalouf, J.; Boonyaratanakornkit, J.; Keane-Candib, J.; Joncas-Schronce, L.; Stevens-Ayers, T.; Dasgupta, S.; Taylor, J.J.; Hirayama, A.V.; et al. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight 2021, 6, e146743. [Google Scholar] [CrossRef]
- Marty, F.M.; Ljungman, P.; Chemaly, R.F.; Maertens, J.; Dadwal, S.S.; Duarte, R.F.; Haider, S.; Ullmann, A.J.; Katayama, Y.; Brown, J.; et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N. Engl. J. Med. 2017, 377, 2433–2444. [Google Scholar] [CrossRef] [PubMed]
- Ljungman, P.; Chemaly, R.F.; Khawaya, F.; Alain, S.; Avery, R.; Badshah, C.; Boeckh, M.; Fournier, M.; Hodowanec, A.; Komatsu, T.; et al. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clin. Infect. Dis. 2024, 79, 787–794. [Google Scholar] [CrossRef] [PubMed]
- Sassine, J.; Khawaja, F.; Shank, B.R.; Lovell, A.; Lee, J.; DiPippo, A.; Rausch, C.R.; Spallone, A.; Ariza Heredia, E.; Chemaly, R.F. Clinically Significant CMV Infections in Patients with Lymphoma or Multiple Myeloma. In Proceedings of the DWeek: Open Forum Infectious Disease, Virtual, 29 September–3 October 2021; pp. S557–S558. [Google Scholar]
- Cheng, J.; Huang, J.; Cao, W.; Huang, L.; Mao, X.; Chen, L.; Zhou, J.; Wang, N. Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up. Front. Immunol. 2023, 14, 1226148. [Google Scholar] [CrossRef]
- Meller, L.; Jagadeesh, V.; Wilson, K.; Oca, M.C.; Sestak, T.; Scott, N. Bilateral Cytomegalovirus Retinitis After Chimeric Antigen Receptor T-cell Therapy for B-cell Lymphoma. Cureus 2024, 16, e56637. [Google Scholar] [CrossRef] [PubMed]
- Bin Dokhi, H.; Alharbi, A.O.; Ibnouf, N.H.; Alahmari, B.; Refka, M.N. Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis. Cureus 2022, 14, e23002. [Google Scholar] [CrossRef] [PubMed]
- Khawaja, F.; Ahmed, S.; Iyer, S.P.; Sassine, J.; Handley, G.; Prakash, R.; VanWierren, T.; Jackson, J.; Zubovskaia, A.; Ramdial, J.; et al. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes. Open Forum Infect. Dis. 2024, 11, ofae422. [Google Scholar] [CrossRef] [PubMed]
- Lin, R.Y.; Anderson, A.D.; Natori, Y.; Raja, M.; Morris, M.I.; Jimenez, A.J.; Beitinjaneh, A.; Wang, T.; Goodman, M.; Lekakis, L.; et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024, 8, 3813–3822. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.; Herr, M.; Nowak, J.; Ho, C.; Almyroudis, N.; Attwood, K.; Bonnewell, J.; Walsh, M.; Segal, B.; Ross, M.; et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica 2023, 108, 615–620. [Google Scholar] [CrossRef]
- Marquez-Algaba, E.; Iacoboni, G.; Pernas, B.; Esperalba, J.; Los Arcos, I.; Navarro, V.; Monforte, A.; Beas, F.; Albasanz-Puig, A.; Carpio, C.; et al. Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy. Transplant. Cell Ther. 2022, 28, 851.e1–851.e8. [Google Scholar] [CrossRef]
- Solano de la Asuncion, C.; Hernani, R.; Albert, E.; Gomez, M.D.; Gimenez, E.; Benzaquen, A.; Gonzalez-Barbera, E.M.; Hernandez-Boluda, J.C.; Perez, A.; Pinana, J.L.; et al. Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: Should it be systematically monitored? Clin. Microbiol. Infect. 2023, 29, 1093–1095. [Google Scholar] [CrossRef]
- Beyar-Katz, O.; Kikozashvili, N.; Bar On, Y.; Amit, O.; Perry, C.; Avivi, I.; Gold, R.; Herishanu, Y.; Benyamini, N.; Duek, A.; et al. Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. Eur. J. Haematol. 2022, 108, 52–60. [Google Scholar] [CrossRef] [PubMed]
- Kampouri, E.; Ibrahimi, S.S.; Xie, H.; Wong, E.R.; Hecht, J.B.; Sekhon, M.K.; Vo, A.; Stevens-Ayers, T.L.; Green, D.J.; Gauthier, J.; et al. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy. Clin. Infect. Dis. 2024, 78, 1022–1032. [Google Scholar] [CrossRef]
- Freeman, R.B., Jr. The ’indirect’ effects of cytomegalovirus infection. Am. J. Transplant. 2009, 9, 2453–2458. [Google Scholar] [CrossRef]
- Sassine, J.; Khawaja, F.; Shigle, T.L.; Handy, V.; Foolad, F.; Aitken, S.L.; Jiang, Y.; Champlin, R.; Shpall, E.; Rezvani, K.; et al. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin. Infect. Dis. 2021, 73, 1346–1354. [Google Scholar] [CrossRef]
- Febres-Aldana, A.; Khawaja, F.; Morado-Aramburo, O.; Shigle, T.L.; Rondon, G.; Sassine, J.; Spallone, A.; Srinivasan, K.; Ramdial, J.; Alousi, A.; et al. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single-centre retrospective experience. Clin. Microbiol. Infect. 2024, 30, 803–809. [Google Scholar] [CrossRef]
- Handley, G.; Hasbun, R.; Okhuysen, P. Human herpesvirus 6 and central nervous system disease in oncology patients: A retrospective case series and literature review. J. Clin. Virol. 2021, 136, 104740. [Google Scholar] [CrossRef] [PubMed]
- Li, N.; Zhang, R.; Wang, J.; Zhu, X.; Meng, F.; Cao, Y.; Wang, G.; Yang, Y. Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. Front. Neurol. 2024, 15, 1334000. [Google Scholar] [CrossRef] [PubMed]
- Spanjaart, A.M.; van der Valk, F.M.; van Rooijen, G.; Brouwer, M.C.; Kersten, M.J. Confused about Confusion. N. Engl. J. Med. 2022, 386, 80–87. [Google Scholar] [CrossRef]
- Handley, G.; Khawaja, F.; Kondapi, D.S.; Lee, H.J.; Kaufman, G.P.; Neelapu, S.S.; Fayad, L.E.; Tummala, S.; Chi, L.; Strati, P.; et al. Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. Int. J. Infect. Dis. 2021, 112, 327–329. [Google Scholar] [CrossRef]
- Khawaja, F.; Sassine, J.; Handley, G.; Prakash, R.; Angelidakis, G.; Ahmed, S.; Ramdial, J.; Nieto, Y.; Rondon, G.; Ariza Heredia, E.; et al. Human Herpes Virus 6 DNAemia within 1 Year of Chimeric Antigen Receptor T Cell Therapy. In Proceedings of the 2023 Tandem Meetings—Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR: Tandem Meetings, Orlando, FL, USA, 15–19 February 2023. [Google Scholar]
- Kampouri, E.; Krantz, E.M.; Xie, H.; Ibrahimi, S.S.; Kiem, E.S.; Sekhon, M.K.; Liang, E.C.; Cowan, A.J.; Portuguese, A.; Green, D.J.; et al. Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients. Blood 2024, 144, 490–495. [Google Scholar] [CrossRef]
- Kampouri, E.; Handley, G.; Hill, J.A. Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)-T Cell Therapy: A Shifting Landscape. Viruses 2024, 16, 498. [Google Scholar] [CrossRef] [PubMed]
- Lareau, C.A.; Yin, Y.; Maurer, K.; Sandor, K.D.; Daniel, B.; Yagnik, G.; Pena, J.; Crawford, J.C.; Spanjaart, A.M.; Gutierrez, J.C.; et al. Latent human herpesvirus 6 is reactivated in CAR T cells. Nature 2023, 623, 608–615. [Google Scholar] [CrossRef]
- Zerr, D.M.; Meier, A.S.; Selke, S.S.; Frenkel, L.M.; Huang, M.L.; Wald, A.; Rhoads, M.P.; Nguy, L.; Bornemann, R.; Morrow, R.A.; et al. A population-based study of primary human herpesvirus 6 infection. N. Engl. J. Med. 2005, 352, 768–776. [Google Scholar] [CrossRef]
- Tau, N.; Shargian-Alon, L.; Reich, S.; Paul, M.; Gafter-Gvili, A.; Shepshelovich, D.; Yahav, D. Reporting infections in clinical trials of patients with haematological malignancies. Clin. Microbiol. Infect. 2019, 25, 1494–1500. [Google Scholar] [CrossRef]
- Cliff, E.R.S.; Reynolds, G.; Popat, R.; Teh, B.W.; Kesselheim, A.S.; Mohyuddin, G.R. Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. J. Clin. Oncol. 2023, 41, 1949–1951. [Google Scholar] [CrossRef]
- Reynolds, G.K.; Maclean, M.; Cliff, E.R.S.; Teh, B.W.; Thursky, K.A.; Slavin, M.A.; Anderson, M.A.; Hawkes, E.A. Infections in patients with lymphoma treated with bispecific antibodies: A systematic review and meta-analysis. Blood Adv. 2024, 8, 3555–3559. [Google Scholar] [CrossRef] [PubMed]
- Longhitano, A.P.; Slavin, M.A.; Harrison, S.J.; Teh, B.W. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Rev. 2021, 49, 100810. [Google Scholar] [CrossRef] [PubMed]
- Moreau, P.; Garfall, A.L.; van de Donk, N.; Nahi, H.; San-Miguel, J.F.; Oriol, A.; Nooka, A.K.; Martin, T.; Rosinol, L.; Chari, A.; et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2022, 387, 495–505. [Google Scholar] [CrossRef] [PubMed]
- Lesokhin, A.M.; Tomasson, M.H.; Arnulf, B.; Bahlis, N.J.; Miles Prince, H.; Niesvizky, R.; Rodriotaguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Touzeau, C.; et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat. Med. 2023, 29, 2259–2267. [Google Scholar] [CrossRef] [PubMed]
- Chari, A.; Minnema, M.C.; Berdeja, J.G.; Oriol, A.; van de Donk, N.; Rodriguez-Otero, P.; Askari, E.; Mateos, M.V.; Costa, L.J.; Caers, J.; et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N. Engl. J. Med. 2022, 387, 2232–2244. [Google Scholar] [CrossRef] [PubMed]
- Florescu, D.F.; Kalil, A.C.; Qiu, F.; Schmidt, C.M.; Sandkovsky, U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am. J. Transplant. 2013, 13, 2601–2610. [Google Scholar] [CrossRef] [PubMed]
- Mathiesen, T.; Brattstrom, C.; Andersson, J.; Linde, A.; Ljungman, P.; Wahren, B. Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections. J. Med. Virol. 1992, 36, 65–69. [Google Scholar] [CrossRef]
- Lejeune, M.; Kose, M.C.; Duray, E.; Einsele, H.; Beguin, Y.; Caers, J. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front. Immunol. 2020, 11, 762. [Google Scholar] [CrossRef]
- Rafei, H.; Rezvani, K. Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies. Br. J. Haematol. 2024, 205, 764–766. [Google Scholar] [CrossRef]
- Philipp, N.; Kazerani, M.; Nicholls, A.; Vick, B.; Wulf, J.; Straub, T.; Scheurer, M.; Muth, A.; Hänel, G.; Nixdorf, D.; et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 2022, 140, 1104–1118. [Google Scholar] [CrossRef] [PubMed]
- Kantarjian, H.; Stein, A.; Gokbuget, N.; Fielding, A.K.; Schuh, A.C.; Ribera, J.M.; Wei, A.; Dombret, H.; Foa, R.; Bassan, R.; et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2017, 376, 836–847. [Google Scholar] [CrossRef]
- Mikulska, M.; Lanini, S.; Gudiol, C.; Drgona, L.; Ippolito, G.; Fernandez-Ruiz, M.; Salzberger, B. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin. Microbiol. Infect. 2018, 24 (Suppl. S2), S71–S82. [Google Scholar] [CrossRef] [PubMed]
- Foa, R.; Bassan, R.; Vitale, A.; Elia, L.; Piciocchi, A.; Puzzolo, M.C.; Canichella, M.; Viero, P.; Ferrara, F.; Lunghi, M.; et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N. Engl. J. Med. 2020, 383, 1613–1623. [Google Scholar] [CrossRef]
- Sanchez-Paz, L.; Tirado Zambrana, P.S.; Villa Poza, C.; Hernandez-Rivas, J.A.; Landete Hernandez, E. Iron deficiency anemia: An early clinical presentation of cytomegalovirus-induced hemorrhagic colitis in chronic myeloid leukemia patients under dasatinib treatment. Ther. Adv. Hematol. 2024, 15, 20406207241291736. [Google Scholar] [CrossRef]
- Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S.K.; Lue, J.K.; Boardman, A.P.; Caron, P.; David, K.A.; Epstein-Peterson, Z.D.; Ghione, P.; et al. Infectious Complicantions in Patients with Relapsed or Refractory (R/R) Non-Hodgkin’s Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (bsAb) Mosunetuzumab. In Proceedings of the 65th ASH Annual Meeting, San Diego, CA, USA, 9–12 December 2023; pp. 4403–4405. [Google Scholar]
- Usmani, S.Z.; Garfall, A.L.; van de Donk, N.; Nahi, H.; San-Miguel, J.F.; Oriol, A.; Rosinol, L.; Chari, A.; Bhutani, M.; Karlin, L.; et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet 2021, 398, 665–674. [Google Scholar] [CrossRef] [PubMed]
- Nooka, A.K.; Rodriguez, C.; Mateos, M.V.; Manier, S.; Chastain, K.; Banerjee, A.; Kobos, R.; Qi, K.; Verona, R.; Doyle, M.; et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer 2024, 130, 886–900. [Google Scholar] [CrossRef]
- Bahlis, N.J.; Costello, C.L.; Raje, N.S.; Levy, M.Y.; Dholaria, B.; Solh, M.; Tomasson, M.H.; Damore, M.A.; Jiang, S.; Basu, C.; et al. Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial. Nat. Med. 2023, 29, 2570–2576. [Google Scholar] [CrossRef]
- Mazahreh, F.; Mazahreh, L.; Schinke, C.; Thanendrarajan, S.; Zangari, M.; Shaughnessy, J.D.; Zhan, F.; van Rhee, F.; Al Hadidi, S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis. Blood Adv. 2023, 7, 3069–3074. [Google Scholar] [CrossRef]
- Sim, B.Z.; Longhitano, A.; Er, J.; Harrison, S.J.; Slavin, M.A.; Teh, B.W. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023, 13, 34. [Google Scholar] [CrossRef]
- Contejean, A.; Janssen, C.; Orsini-Piocelle, F.; Zecchini, C.; Charlier, C.; Chouchana, L. Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study. Am. J. Hematol. 2023, 98, E349–E353. [Google Scholar] [CrossRef]
- Jourdes, A.; Cellerin, E.; Touzeau, C.; Harel, S.; Denis, B.; Escure, G.; Faure, E.; Jamard, S.; Danion, F.; Sonntag, C.; et al. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: A national retrospective study. Clin. Microbiol. Infect. 2024, 30, 764–771. [Google Scholar] [CrossRef] [PubMed]
- Nath, K.; Shekarkhand, T.; Nemirovsky, D.; Derkach, A.; Costa, B.A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.J.; Landau, H.J.; et al. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024, 14, 88. [Google Scholar] [CrossRef]
- Hammons, L.; Szabo, A.; Janardan, A.; Bhatlapenumarthi, V.; Annyapu, E.; Dhakal, B.; Al Hadidi, S.; Radhakrishnan, S.V.; Narra, R.; Bhutani, D.; et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica 2024, 109, 906–914. [Google Scholar] [CrossRef]
- Lancman, G.; Parsa, K.; Kotlarz, K.; Avery, L.; Lurie, A.; Lieberman-Cribbin, A.; Cho, H.J.; Parekh, S.S.; Richard, S.; Richter, J.; et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023, 4, 440–451. [Google Scholar] [CrossRef] [PubMed]
- Raje, N.; Anderson, K.; Einsele, H.; Efebera, Y.; Gay, F.; Hammond, S.P.; Lesokhin, A.M.; Lonial, S.; Ludwig, H.; Moreau, P.; et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer J. 2023, 13, 116. [Google Scholar] [CrossRef]
- Ludwig, H.; Terpos, E.; van de Donk, N.; Mateos, M.V.; Moreau, P.; Dimopoulos, M.A.; Delforge, M.; Rodriguez-Otero, P.; San-Miguel, J.; Yong, K.; et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network. Lancet Oncol. 2023, 24, e255–e269. [Google Scholar] [CrossRef]
- Mohan, M.; Chakraborty, R.; Bal, S.; Nellore, A.; Baljevic, M.; D’Souza, A.; Pappas, P.G.; Berdeja, J.G.; Callander, N.; Costa, L.J. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br. J. Haematol. 2023, 203, 736–746. [Google Scholar] [CrossRef] [PubMed]
CAR-T Product | Number of Patients | CMV Surveillance Protocol | Duration of Follow-Up | % with Any CMV Reactivation | % with CS-CMVi | % with CMV Disease | Risk Factors for CMV | Reference |
---|---|---|---|---|---|---|---|---|
CD19, BCMA | 2256 | None | Median 420 days | 7.5% | N/A | N/A | Not reported | [11] |
CD19 | 230 | Weekly if neutropenia or grade 3/4 CRS/ICANS | 365 days | 22% | 10% | 3% | Asian/Middle Eastern Treatment for CRS/ICANS Meeting criteria for surveillance | [24] |
CD19, BCMA | 95 | None | Median 352 days | 33% | 11% | 0 | 2+ immunosuppressants | [25] |
CD19 | 65 | None | 365 days | 22% | 15% | 1.5% | Not reported | [26] |
CD19 | 105 | Weekly × 4 weeks | Minimum 30 days | 44% | 3% | 0 | Dexamethasone | [27] |
CD19 | 51 | Days 0, 7, 14, 21, 30, 60 and 90 | 90 days | 56% | 6% | 0 | Axicabtagene cileucel | [28] |
CD19 | 60 | Once at 14–21 days | 30 days | 17% | 10% | 0 | Not reported | [29] |
CD19, CD20, BCMA | 72 | Weekly × 12 weeks | 12 weeks | 27% | 7% | 0 | Glucocorticoids > 3 days BCMA CAR-T | [30] |
BsAb Product | Number of Patients | % with Any CMV Reactivation | % with HSV/VZV | Reference |
---|---|---|---|---|
Any | 39 | 18% | 2% | [64] |
Any | 90 | 3% (No CMV disease) | - | [68] |
BCMA | 37 | 22% (11% CS-CMVi, 6% CMV disease) | - | [69] |
BCMA | 188 | 9% | 0.5% | [65] |
BCMA, GPRC5D | 229 | 3.5% | 1% | [66] |
BCMA | 55 | 4% | 5% | [67] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sassine, J.; Siegrist, E.A.; Chemaly, R.F. Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review. Viruses 2025, 17, 133. https://doi.org/10.3390/v17010133
Sassine J, Siegrist EA, Chemaly RF. Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review. Viruses. 2025; 17(1):133. https://doi.org/10.3390/v17010133
Chicago/Turabian StyleSassine, Joseph, Emily A. Siegrist, and Roy F. Chemaly. 2025. "Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review" Viruses 17, no. 1: 133. https://doi.org/10.3390/v17010133
APA StyleSassine, J., Siegrist, E. A., & Chemaly, R. F. (2025). Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review. Viruses, 17(1), 133. https://doi.org/10.3390/v17010133